Harte Hanks reported Q1 2026 results on May 14, with the numbers landing on the wrong side of expectations — and doing little to disrupt the narrative that shorts had been quietly rebuilding into.
Revenue fell to $37.3 million, down from $41.6 million a year earlier. EPS came in at -$0.08, worse than the -$0.05 loss in the prior-year quarter. The top-line decline extends a multi-year contraction: full-year 2025 sales of $159.6 million compared to $185.2 million in 2024, a drop of nearly 14%. The Q4 2025 print had briefly offered a reason for optimism — net income turned positive at $2.2 million — but the Q1 figures suggest that recovery was not the start of a trend.
Short interest tells the same story the data was pointing to before the print. Estimated short positions roughly doubled over the past month, rising 66% to around 54,600 shares by mid-May. That build began in earnest in mid-April, climbing from roughly 32,000 shares to above 55,000 in a matter of weeks — a clear signal that bearish conviction was growing ahead of the release. Borrowing costs remained modest at around 2%, and availability showed no signs of tightening, meaning there was nothing to deter that accumulation.
The ownership picture underscores how tightly held this micro-cap is. Gary Rosenbach controls roughly 29% of shares. The Harte family estate holds another 9%. William Blair rounds out the top three with just under 9%. Together, three holders account for nearly half the float — a structure that can amplify volatility on earnings days but also constrains how aggressively shorts can build. With a market cap of just over $20 million and days to cover running above seven, even a modest price move can become consequential in either direction.
With the Q1 miss now confirmed and revenue contraction showing no sign of reversal, the May 18 formal reporting event will test whether management can offer a credible path to stabilisation — or whether the market treats this as one more data point in a prolonged structural decline.
See the live data behind this article on ORTEX.
Open HHS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
